BPC-157
Also known as: Body Protection Compound-157, Pentadecapeptide BPC 157
Buy in shop
BPC-157
5 verified vendors, side by side on real prices.
Key Facts: BPC-157
- Category
- Healing
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - FDA removed BPC-157 from Category 2 "do not compound" list effective April 22, 2026. PCAC voted 8-6 to recommend BPC-157 for the 503A authorized compounding bulks list on July 23, 2026. This is a non-binding advisory recommendation; FDA must complete formal notice-and-comment rulemaking (typically 12-24 months) before any legal compounding change takes effect. No FDA approval for any indication. Effective October 30, 2026, HHS published Federal Register Document 2026-22192, an interim enforcement discretion policy that conditionally permits 503A compounding pharmacies to compound BPC-157 while formal rulemaking proceeds. Conditions include pharmaceutical-grade API sourcing, certificates of analysis, patient-specific prescriptions only, and single-API formulations only. This does not add BPC-157 to the FDA 503A Bulks Drug Substances List and is not a final rule. Rulemaking is pending with no timeline stated.
- Banned in Sport (WADA)
- Prohibited at all times under WADA S0 (non-approved substances), where BPC-157 is named directly.
- Administration
- Subcutaneous injection near injury site, or systemic
- Typical Dose
- 250-500 mcg twice daily
- Frequency
- 1-2x daily
- Duration
- 4-12 weeks in most research protocols
How does BPC-157 work?
The leading hypothesis is that BPC-157 promotes new blood vessel growth by upregulating the VEGFR2 receptor, the same receptor that drives angiogenesis, and by tapping into the nitric oxide system through the Akt-eNOS pathway. Better blood supply to injured tissue would, in theory, speed healing of tendons, muscle, and gut lining. Animal work also points to anti-inflammatory effects and interaction with growth-factor signaling. It is worth being blunt here: these mechanisms are mostly worked out in rodents, and the exact molecular target of BPC-157 has never been definitively pinned down. Treat the pathway story as a well-supported hypothesis, not settled fact.
What does the research show?
The preclinical record is genuinely large. A 2025 narrative review in the journal Biomedicines counted hundreds of published animal studies showing BPC-157 accelerating healing across tendon, muscle, bone, gut, liver, and nervous-system injury models. The problem is the human side is nearly empty. That same review found only three published human pilot studies (knee pain injections, bladder injections for interstitial cystitis, and an intravenous safety trial) and concluded BPC-157 should be treated as investigational and not recommended for clinical use until proper trials exist. Pharmacokinetic work in rats and dogs found a very short elimination half-life (under 30 minutes after injection) and rapid breakdown into amino acid fragments, which raises real questions about how oral capsules sold online could deliver an intact peptide. Bottom line: lots of promising animal data, no completed randomized controlled trials in people, and no regulatory approval anywhere.
What doses have been studied?
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
250-500 mcg twice daily
200-1,000 mcg per day total
1-2x daily
Reported research use describes administration near the site of interest as well as systemic administration, with the daily amount commonly divided between morning and evening.
Research Dosingⓘ
Scientific studies
Doses observed in research studies
Doses from Studies
250-500 mcg twice daily
200-300 mcg/kg in animal studies
Duration
4-12 weeks in most research protocols
Administration
Subcutaneous injection near injury site, or systemic
When and how is BPC-157 taken?
Best Time to Take
Morning and evening (or near injury site timing)
1-2 times daily, consistent timing
Food Recommendation
With or without food
Why This Timing?
BPC-157 has systemic healing effects. Split dosing maintains stable levels. Can be timed around activity for injury healing.
What are the side effects of BPC-157?
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated in preclinical studies
- ●Nausea
- ●Dizziness
- ●Injection site reactions
- ●Fatigue
- ●Headache
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Potential concern for tumor promotion (angiogenesis)
- ●Limited long-term human safety data
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
- https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1026182/full
- https://en.wikipedia.org/wiki/BPC-157
- https://pubmed.ncbi.nlm.nih.gov/7901724/
- https://www.federalregister.gov/documents/2026/10/30/2026-22192/compounding-enforcement-discretion-503a
Research This Peptide Further
Buy in shop
BPC-157
5 verified vendors, side by side on real prices.
Frequently Asked Questions
What does BPC-157 do?
BPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) based on a fragment of a protective protein found in human gastric juice. It is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. The catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof.
How does BPC-157 work?
The leading hypothesis is that BPC-157 promotes new blood vessel growth by upregulating the VEGFR2 receptor, the same receptor that drives angiogenesis, and by tapping into the nitric oxide system through the Akt-eNOS pathway. Better blood supply to injured tissue would, in theory, speed healing of tendons, muscle, and gut lining. Animal work also points to anti-inflammatory effects and interaction with growth-factor signaling. It is worth being blunt here: these mechanisms are mostly worked out in rodents, and the exact molecular target of BPC-157 has never been definitively pinned down. Treat the pathway story as a well-supported hypothesis, not settled fact.
Is BPC-157 FDA approved?
No, BPC-157 is not currently FDA approved. Current status: Preclinical - FDA removed BPC-157 from Category 2 "do not compound" list effective April 22, 2026. PCAC voted 8-6 to recommend BPC-157 for the 503A authorized compounding bulks list on July 23, 2026. This is a non-binding advisory recommendation; FDA must complete formal notice-and-comment rulemaking (typically 12-24 months) before any legal compounding change takes effect. No FDA approval for any indication. Effective October 30, 2026, HHS published Federal Register Document 2026-22192, an interim enforcement discretion policy that conditionally permits 503A compounding pharmacies to compound BPC-157 while formal rulemaking proceeds. Conditions include pharmaceutical-grade API sourcing, certificates of analysis, patient-specific prescriptions only, and single-API formulations only. This does not add BPC-157 to the FDA 503A Bulks Drug Substances List and is not a final rule. Rulemaking is pending with no timeline stated.
Is BPC-157 banned in sport?
Prohibited at all times under WADA S0 (non-approved substances), where BPC-157 is named directly.
What are the side effects of BPC-157?
Reported side effects include: Generally well-tolerated in preclinical studies, Nausea, Dizziness, Injection site reactions, Fatigue. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of BPC-157?
Community-reported common dose: 250-500 mcg twice daily (1-2x daily). Range: 200-1,000 mcg per day total. Administration: Subcutaneous injection near injury site, or systemic. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with BPC-157 or used in similar applications.
TB-500
PreclinicalTB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
HealingGHK-Cu
Clinical TrialsGHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Skin & HairPentadecapeptide
PreclinicalPentadecapeptide almost always means BPC-157, a synthetic 15-amino-acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. It is one of the most hyped 'healing' peptides online, marketed for tendon, gut, and muscle repair, but here is the catch: essentially all of the supporting evidence is from rats and mice. There is no FDA approval and no completed human clinical trial proving it does any of this.
HealingB7-33
PreclinicalB7-33 is a 27-amino-acid, single-chain peptide cut down from the B-chain of human relaxin-2, the hormone that loosens tissue during pregnancy. Relaxin itself has strong anti-scarring effects but is a complex two-chain molecule that is hard and expensive to make, so an Australian group (Hossain and colleagues, 2016) designed B7-33 as a simpler version. In rodent models it reduced heart and lung fibrosis about as well as full relaxin. It has never been tested in humans.
HealingThymosin Beta-4
Clinical TrialsThymosin beta-4 (Tbeta4) is a small 43 amino acid peptide found in nearly every cell in the body, originally isolated from the thymus. Its main job is binding and sequestering G-actin, the building block of the cell's internal scaffolding, which lets it influence cell movement, wound repair, and tissue regeneration. It is researched heavily for healing of skin, cornea, and heart tissue, but it is not an FDA-approved drug. (The injectable sold as TB-500 is a synthetic fragment marketed as related to Tbeta4, not the full natural peptide.)
HealingZiconotide
FDAZiconotide is a real, FDA-approved painkiller pulled from the venom of a marine cone snail. It is not an opioid, and unlike morphine, people do not build tolerance to it over time. The catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning.
HealingWant updates on BPC-157 research?
Get an email when we add new research here, when it is back in stock, or when the price drops.